5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemother

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab is a phase 2, interventional study registered as NCT07124884 by Federation Francophone de Cancerologie Digestive, with a registry enrolment figure of 300 participants, started 2025-08-31 and due to reach its primary completion in 2030-06-30. Interventions recorded: Administration of experimental treatment association (sotorasib, panitumumab 5FU). Conditions listed: Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer. Primary outcome: Percentage of patient alive or without progression 8 months after inclusion.. Colorectal eligibility wording from the registry: "* Histologically proven advanced-stage unresectable locally advanced or metastatic colorectal adenocarcinoma". Sites: France, Germany, Italy, Spain. No results are recorded here; the registry entry is the source.